title: Clarification of trial end points presented in a recent review of linaclotide.
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Johnston
authors.forename: Harvey A
authors.initials: HA
authors.lastname: Schneier
mesh_terms: D000818:Animals; D003248:Constipation / Q000188:drug therapy*; D020536:Enzyme Activators / Q000627:therapeutic use*; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000188:drug therapy*; D010455:Peptides / Q000627:therapeutic use*; D050705:Receptors, Guanylate Cyclase-Coupled / Q000819:agonists*
chemical_list: D020536:Enzyme Activators; D005765:Gastrointestinal Agents; D010455:Peptides; D050705:Receptors, Guanylate Cyclase-Coupled